Screening for prostate cancer remains a contentious issue. As with other cancer screening programs, a key feature of the debate is verification of cancer-specific mortality reductions …
RM Hoffman - New England Journal of Medicine, 2011 - Mass Medical Soc
Key Clinical Points Prostate-Cancer Screening The introduction of prostate-specific antigen (PSA) testing has nearly doubled the lifetime risk of receiving a diagnosis of prostate cancer …
FH Schröder - Urologic Oncology: Seminars and Original …, 2008 - Elsevier
Introduction for screening for prostate cancer as a healthcare policy is desirable provided its effectiveness can be shown in terms of decreasing prostate cancer mortality at an …
P Tenke, J Horti, P Balint, B Kovacs - Prostate Cancer, 2007 - Springer
Prostate cancer is a major healthcare problem worldwide, especially in the industrialized countries of the Western world. Prostate cancer has become the most common type of …
The debate about usefulness of population-based prostate cancer screening has been ongoing for decades, with little consensus among professional medical societies, cancer …
SS Wilson, ED Crawford - Urologic Clinics, 2004 - urologic.theclinics.com
An estimated 220,900 new cases of prostate cancer were diagnosed in the United States in 2003, and 28,900 men died of the disease during that year [1]. A global effort to decrease …
Task Force (USPSTF) states that evidence is insufficient to assess the risks and benefits of prostate cancer screening in men younger than 75 years. Other major international health …
ED Cook, AC Nelson - Current oncology reports, 2011 - Springer
Prostate cancer is the most common cancer and the second leading cause of cancer-related deaths in American men. Although the use of the prostate-specific antigen (PSA) test for …
OBJECTIVE• To determine whether screening for prostate cancer reduces prostate cancer‐ specific mortality, impact on all‐cause mortality and patient health‐related quality of life …